XTX Topco Ltd Has $1.35 Million Stake in Penumbra, Inc. (NYSE:PEN)

XTX Topco Ltd lifted its stake in Penumbra, Inc. (NYSE:PEN - Free Report) by 111.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,664 shares of the company's stock after acquiring an additional 2,984 shares during the quarter. XTX Topco Ltd's holdings in Penumbra were worth $1,345,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new position in Penumbra during the fourth quarter worth $54,396,000. Baillie Gifford & Co. grew its position in shares of Penumbra by 23.4% in the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock valued at $173,416,000 after acquiring an additional 138,387 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Penumbra by 39.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company's stock worth $71,831,000 after purchasing an additional 85,284 shares during the last quarter. WCM Investment Management LLC bought a new stake in shares of Penumbra in the 4th quarter valued at about $13,451,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Penumbra in the 3rd quarter valued at about $6,995,000. Institutional investors own 88.88% of the company's stock.

Penumbra Price Performance

PEN traded down $1.17 on Friday, hitting $276.62. 326,817 shares of the stock were exchanged, compared to its average volume of 414,071. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of 813.60, a PEG ratio of 2.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The business has a 50-day moving average of $275.47 and a two-hundred day moving average of $252.06.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business had revenue of $315.52 million for the quarter, compared to analysts' expectations of $311.63 million. Sell-side analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity at Penumbra

In related news, CEO Adam Elsesser sold 61,600 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the sale, the chief executive officer now owns 16,376 shares in the company, valued at $4,644,069.84. The trade was a 79.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Lambert Shiu sold 501 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total value of $141,722.88. Following the completion of the transaction, the chief accounting officer now owns 32,969 shares of the company's stock, valued at $9,326,270.72. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 127,846 shares of company stock valued at $35,779,187 over the last ninety days. 5.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. UBS Group upped their price objective on Penumbra from $305.00 to $320.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. StockNews.com downgraded Penumbra from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Truist Financial decreased their price objective on shares of Penumbra from $325.00 to $315.00 and set a "buy" rating on the stock in a report on Friday, April 11th. JPMorgan Chase & Co. raised their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Penumbra currently has a consensus rating of "Moderate Buy" and a consensus price target of $293.93.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.